NASDAQ:IRON Disc Medicine Q3 2024 Earnings Report $74.38 -1.77 (-2.32%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$74.56 +0.18 (+0.24%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Disc Medicine EPS ResultsActual EPS-$0.89Consensus EPS -$1.04Beat/MissBeat by +$0.15One Year Ago EPSN/ADisc Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADisc Medicine Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETUpcoming EarningsDisc Medicine's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Disc Medicine Earnings HeadlinesRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONJuly 20 at 6:30 PM | prnewswire.comJohn Quisel Sells 33,000 Shares of Disc Medicine (NASDAQ:IRON) StockJuly 16, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 21 at 1:00 AM | Chaikin Analytics (Ad)Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJuly 15, 2026 | globenewswire.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONJuly 14, 2026 | prnewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJuly 11, 2026 | globenewswire.comSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins. Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.View Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
